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generally slower than that of the comparator group, i.e. 1.21±
0.21 vs. 1.31± 0.23 m/s (p= 0.017). Despite diminished walking
speed, the external knee AddM was significantly higher in the
OA group than in the comparator group (2.9±0.7 vs. 2.2±0.7;
p<.001), while the hip AddM was reduced (3.9±0.8 vs. 4.3 ±0.9,
p=0.02). After completion of the strengthening program, the
self-selected normal speed of the four pilot patients increased
by 5.6% compared to the initial base values. In addition, the
external the knee AddM decreased by 3.6%, while the hip AddM
increased by 9.6%.
Conclusions: In accordance with previous observations, these
data suggest that in mild knee OA, the increased loading at
the knee is accompanied by decreased loading at the hip. The
chronically reduced recruitment of hip abductors stabilizing the
external hip AddM may result in hip muscle weakness over time,
and thus cause an unstable pelvis during gait yielding higher
medial loads at the knee. In our pilot patients, a focused hip
muscle strengthening program favorably altered both hip and
knee joint moments in subjects with knee OA, likely through
postural adaptations at the trunk and pelvis during gait. This
initial work suggests that focused muscle strengthening may
be a promising intervention for reducing medial compartment
loading patterns in subjects with knee OA.
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Purpose: Loss of meniscus tissue frequently leads to decreased
clinical function and activity levels. However, no report has quan-
tified the amount of meniscus tissue removed at meniscectomy
and correlated the meniscus tissue loss with clinical symptoms,
function, and activity. The purpose of this study was to determine,
prospectively, the amount of tissue loss at time of partial medial
meniscectomy and then correlate extent of meniscus loss with
clinical symptoms, function, and activity levels 2 years following
the index meniscectomy.
Methods: In a randomized controlled investigational device clin-
ical trial (Level of Evidence I), 149 patients 18 to 60 years old
underwent partial medial meniscectomy and served as controls.
There were 81 acute (no prior meniscus surgery) and 68 chronic
(1 to 3 prior partial meniscectomies on the involved meniscus)
patients. At index surgery, size of the meniscus defect was
measured using specially designed instruments, and percent of
meniscus loss was calculated based on actual measurements.
Patients were followed clinically for a minimum of 2 years follow-
ing meniscectomy. At each follow-up, every patient completed
questionnaires including Lysholm and Tegner scores to assess
function and activity. Amount of meniscus tissue at index surgery
was correlated with the individual domains of the Lysholm scale.
Tegner index was calculated to determine the amount of lost
activity regained 2 years after surgical intervention.
Results: Two-year data were available for 127 patients
(85% follow-up). There was a significant correlation between
the amount of meniscus tissue remaining following the in-
dex meniscectomy and 2-year Lysholm domains of squat-
ting (r=0.281, p=0.001), stair-climbing (r=0.251, p=0.004), and
swelling (r=0.261, p=0.003). In particular, it is noteworthy that
patients who had >50% of their meniscus remaining had sig-
nificantly better function than patients who had <50% menis-
cus remaining. Patients who had worse or no improvement in
pain symptoms at 2 years averaged 42% meniscus remaining,
while patients who had improved pain scores had on average
51% meniscus remaining. Tegner index for patients with <50%
meniscus remaining averaged 24%, and for patients with >50%
meniscus remaining averaged 52% (p=0.017); hence, a greater
amount of meniscus tissue remaining allowed patients to regain
significantly more of their lost activity.
Conclusions: There is a significant correlation between the
amount of meniscus tissue removed at meniscectomy and symp-
toms, function, and activity 2 years after surgery. This study con-
firms the importance of preserving as much meniscus tissue as
possible at the time of meniscus repair or meniscectomy as well
as the potential positive benefits of regrowing or replacing lost
meniscus tissue in order to minimize clinical symptoms that may
be suggestive of early degenerative changes.
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Purpose: RN624 is a humanized IgG2 monoclonal antibody
against human nerve growth factor (NGF). NGF is elevated in
conditions of acute and chronic pain and facilitates the impulse
flow in sensory neurons. RN624 has been effective in animal
pain models including arthritis pain, cancer pain and incision
pain. The objective of the first in human clinical study, Protocol
RN624-CL001, was to evaluate the safety and activity of a single
intravenous dose of RN624 in subjects with pain due to knee
OA.
Methods: 121 subjects with knee OA and a knee pain of ≥25
(VAS 0-100) were enrolled in a phase 1 double blinded, random-
ized, placebo controlled trial. The study was conducted in two
parts; a dose escalation (Part 1) followed by a parallel arm (Part
2). 42 subjects (12 placebo, 30 active) were enrolled in 5 dose
escalation cohorts to receive 3, 10, 30, 100, 300, and 1000 μg/kg
RN624 or placebo with 28 days inter-cohort intervals. Once the
safety of RN624 was established in Part 1, 79 subjects were en-
rolled in Part 2 and received either 100 or 300 μg/kg RN624 or
placebo in parallel (N = 27, 26 and 26 respectively). All subjects
received a single infusion of RN624 and were followed for up
to 180 days. Subjects recorded pain scores (VAS 0-100) for the
index knee 4 times a day and walking pain once a day or 28
days in the 3, 10, 30 μg/kg doses and up to 180 days in higher
dose groups. The WOMAC scale was administered during office
visits.
Results: Significant reduction in overall knee pain and walking
pain was observed in doses of 10 μg/kg RN624 and higher
of RN624. The peak effect was achieved by week 4 and was
sustained up to 12 weeks in 100 μg/kg and higher. More than
50% of subjects in 100 μg/kg or higher groups (N=71) experi-
enced at least a 50% reduction in walking pain over 12 weeks
compared to 25% in their placebo counterparts (N=32). A subset
of subjects in 100 μg/kg or higher displayed a transient reduced
efficacy in the 2nd and 3rd weeks; they experienced pain reduc-
tion during the 1st week, decreased pain reduction during the 2nd
and 3rd weeks, and sustained pain reduction up to 12 weeks.
Approximately 55% of subjects who received a single infusion of
100 μg/kg RN624 or higher achieved at least 50% improvement
in WOMAC function and stiffness subscales over 12 weeks post
infusion.
Approximately 25% of RN624 subjects reported adverse events
of altered or abnormal sensation of pain such as dysesthesia,
parasthesia, hyperesthesia, and allodynia. None of these events
were reported in the 3, 10, or 30 μg/kg RN624 groups (N=12).
These events were generally mild to moderate in severity and
transient. They mostly emerged during the first 2 weeks and
